Evidence uncovered at the headquarters of Solgar Polska indicates the firm has since 2010 been instructing retailers to fix prices for its wide range of supplements, according to the national competition regulator. The company is now facing a full investigation and potentially a substantial fine.
Poland’s Office of Competition and Consumer Protection, UOKiK, has launched an investigation into suspected price fixing over a period of almost a decade by Solgar Polska, an independent, third-party distributor of The Nature’s Bounty Co.’s Solgar dietary supplements brand.
A search conducted by UOKiK at Solgar Polska’s office in Warsaw uncovered documentary evidence, including email correspondence, that the company...
In a major milestone for the EU’s pricing and reimbursement landscape, the European Commission has published the first ever, much anticipated, joint clinical assessment report.
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
Weak demand for virus-blocking nasal sprays since the pandemic has left Austrian biotech Marinomed with mounting debts. The company has applied for restructuring proceedings with an Austrian court in an attempt to secure its future.
Perrigo aims its new SolpaOne high-strength paracetamol effervescent at UK pharmacists, who now have expanded powers as part of the UK government's Pharmacy First initiative.
Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.
